Will Adaptimmune Therapeutics's price keep soaring?

Will Adaptimmune Therapeutics's price keep soaring?

Article image

Studies by leading experts into the power of price momentum show that stocks with the strongest price trends tend to keep up the pace for anywhere up to one year. A big part of the reason for this is down to investor psychology. 

With that in mind, shares in Adaptimmune Therapeutics (NSQ:ADAP) have been in an uptrend in recent months, and the question now for investors is whether that price strength will continue.

Knowing exactly what drives relative strength in share prices can help you find profitable trades based on momentum – and Adaptimmune Therapeutics might just fit the bill.

Adaptimmune Therapeutics (NSQ:ADAP)'s performance to date

Adaptimmune Therapeutics operates in the Biotechnology & Medical Research industry and in terms of relative price strength the stock has performed well against the market over the past year:

  • 1 Month: 43.1%
  • 6 Months: 601.8%
  • 12 Months: 36.4%

Relative strength is a useful tool in the armoury of technical traders and investors. It’s an instant measure of how a stock has performed in comparison with a benchmark.

And while there are no certainties about which way a stock will move next, research shows that price trends often persist. Why is this? Studies broadly show it is down to:

  • Initial under-reaction by investors- prices are slow to move up because investors are hesitant to bid prices higher in stocks that have already been on a strong run.
  • Delayed over-reaction - investors chasing rising prices attract the attention of other investors, who follow them into those trades, pushing prices higher and higher.

In both cases, stocks with positive price momentum often see their prices trend higher.


What does this mean for potential investors?

Adaptimmune Therapeutics is currently among the stocks with the strongest six-month and one-year relative price strength in the market. But momentum on its own is no guarantee of future returns. 

To get a better idea about whether this momentum will continue, it's worth doing some investigation yourself. Indeed, we've identified some areas of concern with Adaptimmune Therapeutics that you can find out about here.


About us

Stockopedia helps individual investors make confident, profitable choices in the stock market. Our StockRank and factor investing toolbox unlocks institutional-quality insights into thousands of global stocks. Voted “Best Investment Research Tools” and “Best Research Service” at the 2021 UK Investor Magazine awards.

Adaptimmune Therapeutics's StockRank™

Momentum TrapSpeculative

Adaptimmune Therapeutics's StockRank™

With a StockRank of 34, Adaptimmune Therapeutics is in the bottom 34% of the 9,669 stocks we cover in North America, according to our proprietary ranking system.

See the full StockReport

Absolutely Perfect

"Trialed multiple other platforms - this is by far my favourite. Other platforms do not even have half the stuff that you can find on Stockopedia. Love it!"

As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested.